HomeComparePNAGF vs ABBV

PNAGF vs ABBV: Dividend Comparison 2026

PNAGF yields 4.42% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $81.8K in total portfolio value
10 years
PNAGF
PNAGF
● Live price
4.42%
Share price
$3.96
Annual div
$0.18
5Y div CAGR
-45.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.6K
Annual income
$1.05
Full PNAGF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — PNAGF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPNAGFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PNAGF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PNAGF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PNAGF
Annual income on $10K today (after 15% tax)
$375.89/yr
After 10yr DRIP, annual income (after tax)
$0.89/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $21,055.11/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PNAGF + ABBV for your $10,000?

PNAGF: 50%ABBV: 50%
100% ABBV50/50100% PNAGF
Portfolio after 10yr
$61.5K
Annual income
$12,386.41/yr
Blended yield
20.15%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

PNAGF
No analyst data
Altman Z
5.2
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PNAGF buys
0
ABBV buys
0
No recent congressional trades found for PNAGF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPNAGFABBV
Forward yield4.42%3.06%
Annual dividend / share$0.18$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-45.6%40.6%
Portfolio after 10y$20.6K$102.3K
Annual income after 10y$1.05$24,771.77
Total dividends collected$535.00$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PNAGF vs ABBV ($10,000, DRIP)

YearPNAGF PortfolioPNAGF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,941$240.57$11,550$430.00$609.00ABBV
2$11,840$133.81$13,472$627.96$1.6KABBV
3$12,743$73.63$15,906$926.08$3.2KABBV
4$13,675$40.29$19,071$1,382.55$5.4KABBV
5$14,654$21.98$23,302$2,095.81$8.6KABBV
6$15,692$11.98$29,150$3,237.93$13.5KABBV
7$16,797$6.52$37,536$5,121.41$20.7KABBV
8$17,976$3.55$50,079$8,338.38$32.1KABBV
9$19,236$1.93$69,753$14,065.80$50.5KABBV
10$20,584$1.05$102,337$24,771.77$81.8KABBV

PNAGF vs ABBV: Complete Analysis 2026

PNAGFStock

PETRONAS Gas Berhad operates as a gas infrastructure and utilities company in Malaysia. The company engages in separating natural gas into components; and storing, transporting, distributing, and selling such components to industrial utilities. It operates through four segments: Gas Processing, Gas Transportation, Regasification, and Utilities. The Gas Processing segment processes natural gas from the gas fields of the East Coast of Peninsular Malaysia into sales gas and other by-products, such as ethane, propane, and butane. The Gas Transportation segment engages in the transportation of sales gas through its 2,623 kilometers of peninsular gas utilization pipeline network, as well as pengerang gas pipeline network. It also transports small volumes of sales gas through its gas distribution system in Miri and Bintulu, and Sarawak; exports sales gas to Singapore; and offers operation and maintenance services. The Regasification segment engages in the regasification of liquefied natural gas (LNG), as well as provides LNG reloading, truck loading, and gassing up and cooling down services. The Utilities segment manufactures, markets, and supplies industrial utilities to the petrochemical complexes in the Kertih and Gebeng Industrial Area. This segment offers electricity, steam, and industrial gases; and operations and maintenance services, as well as other utility products, such as oxygen, nitrogen, demineralized water, raw water, cooling water, and boiler feed water to petrochemical complexes and national electricity grid. The company was incorporated in 1983 and is based in Kuala Lumpur, Malaysia. PETRONAS Gas Berhad is a subsidiary of Petroliam Nasional Berhad.

Full PNAGF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this PNAGF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PNAGF vs SCHDPNAGF vs JEPIPNAGF vs OPNAGF vs KOPNAGF vs MAINPNAGF vs JNJPNAGF vs MRKPNAGF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.